Tumours expressing progesterone receptor (PR) and/or estrogen receptor (ER) are considered hormone receptor-positive breast cancers, while in triple-negative breast cancer (TNBC), tumours do not express any of these receptors. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.